

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

VOLUNTARY ANNOUNCEMENT REGISTRATION IN THAILAND FOR VITAFLOW LIBERTY™

This announcement is made by MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement and product registration progress of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that our independently-developed new-generation transcatheter aortic valve implantation (“**TAVI**”) product, the VitaFlow Liberty™ transcatheter aortic valve implantation system (“**VitaFlow Liberty™**”), and Alwide® Plus balloon catheter (“**Alwide® Plus**”) were registered in Thailand successively.

As our independently-developed new-generation TAVI product, VitaFlow Liberty™ not only inherits the advantages of the VitaFlow® transcatheter aortic valve implantation system (“**VitaFlow®**”) in valve design, but also achieves a breakthrough upgrade of the delivery system. VitaFlow Liberty™ has rapidly penetrated qualified domestic medical centers and grown its market share upon approval by the National Medical Products Administration of the People’s Republic of China in August 2021. Its CE mark registration is also under review. After the successful registration of VitaFlow Liberty™ in Argentina and Colombia in December 2021 and August 2022 respectively, we have completed nearly 100 commercial implantations overseas, during which its ease-of-use, accuracy of prosthetic aortic valve positioning and optimized perivalvular leakage prevention and hemodynamic performance received high praises by physicians.

We believe that the registration of VitaFlow Liberty™ in Thailand marks another solid step forward on our international roadmap. We will begin commercialization of this product in the Asia Pacific markets immediately and continue to leverage the global reputation of the MicroPort® brand and the existing sales network of the MicroPort® Group to enhance the promotion of our VitaFlow® family products globally. We will also strive to enter more global markets and continuously promote R&D innovation to benefit more patients around the world with high quality and universally-accessible total solutions for the treatment of structural heart diseases.

By order of the Board
MicroPort CardioFlow Medtech Corporation
Luo Qiyi
Chairman

Shanghai, PRC, February 21, 2023

As of the date of this announcement, the executive Directors are Mr. Chen Guoming, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Dr. Luo Qiyi, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.